Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase
Status:
Completed
Trial end date:
2020-10-22
Target enrollment:
Participant gender:
Summary
Pegylated-asparaginase (PEG-ASP) is an important part of the treatment of childhood acute
lymphoblastic leukaemia (ALL). Unfortunately 13% of patients develops allergy and further
treatment is impossible. Furthermore, 6% of patients have developed antibodies (silent
inactivation) and have no effect of the PEG-ASP treatment. Truncated asparaginase therapy is
associated with inferior event-free survival outcomes, in particular relapse in central
nervous system (CNS).
Eryaspase is a new formulation of asparaginase encapsulated in erythrocytes. The erythrocyte
membrane protects asparaginase against fast degradation and elimination processes. The
encapsulation eliminates the direct somatic contact, and it is hypothesized that this
provides the potential to prolong the activity of the enzyme and reduce toxicities.